Recent Investment Analysts’ Ratings Updates for Axsome Therapeutics (AXSM)

Axsome Therapeutics (NASDAQ: AXSM) recently received a number of ratings updates from brokerages and research firms:

• 5/5/2026 – Axsome Therapeutics was given a new $280.00 price target by Deutsche Bank Aktiengesellschaft.
• 5/5/2026 – Axsome Therapeutics had its price target raised by Needham & Company LLC from $225.00 to $255.00. They now have a “buy” rating on the stock.
• 5/5/2026 – Axsome Therapeutics had its price target raised by Royal Bank Of Canada from $242.00 to $302.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Axsome Therapeutics had its price target raised by HC Wainwright from $270.00 to $290.00. They now have a “buy” rating on the stock.
• 5/5/2026 – Axsome Therapeutics had its price target raised by Morgan Stanley from $217.00 to $242.00. They now have an “equal weight” rating on the stock.
• 5/5/2026 – Axsome Therapeutics had its price target raised by Wells Fargo & Company from $225.00 to $255.00. They now have an “overweight” rating on the stock.
• 5/5/2026 – Axsome Therapeutics had its price target raised by Mizuho from $228.00 to $310.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Axsome Therapeutics had its price target raised by Robert W. Baird from $241.00 to $246.00. They now have an “outperform” rating on the stock.
• 5/4/2026 – Axsome Therapeutics was given a new $280.00 price target by Oppenheimer Holdings, Inc..
• 5/4/2026 – Axsome Therapeutics had its price target raised by Guggenheim from $245.00 to $260.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Axsome Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $258.00 price target on the stock.
• 5/4/2026 – Axsome Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $272.00 price target on the stock.
• 5/4/2026 – Axsome Therapeutics had its price target raised by Jefferies Financial Group Inc. from $245.00 to $275.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $281.00 price target on the stock.
• 5/4/2026 – Axsome Therapeutics had its price target raised by HC Wainwright from $260.00 to $270.00. They now have a “buy” rating on the stock.
• 5/1/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 5/1/2026 – Axsome Therapeutics had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $250.00 price target on the stock.
• 5/1/2026 – Axsome Therapeutics had its price target raised by Needham & Company LLC from $225.00 to $255.00. They now have a “buy” rating on the stock.
• 4/30/2026 – Axsome Therapeutics was given a new $217.00 price target by Morgan Stanley.
• 4/20/2026 – Axsome Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/10/2026 – Axsome Therapeutics had its price target raised by UBS Group AG from $251.00 to $259.00. They now have a “buy” rating on the stock.
• 3/25/2026 – Axsome Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/25/2026 – Axsome Therapeutics had its price target raised by Guggenheim from $220.00 to $245.00. They now have a “buy” rating on the stock.

Insider Activity

In other news, Director Mark Coleman sold 25,000 shares of Axsome Therapeutics stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $161.11, for a total value of $4,027,750.00. Following the completion of the transaction, the director owned 47,140 shares in the company, valued at approximately $7,594,725.40. This trade represents a 34.65% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Ari Maizel sold 7,500 shares of Axsome Therapeutics stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $182.42, for a total value of $1,368,150.00. Following the completion of the transaction, the insider owned 7,500 shares of the company’s stock, valued at $1,368,150. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 72,628 shares of company stock worth $12,205,662. 20.60% of the stock is currently owned by company insiders.

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.